Brexpiprazole: A new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder

Drugs of Today

Volumn 51, Issue 7, 2015, Pages 397-414

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Brexpiprazole; Dopamine D2 receptor partial agonist; Major depressive disorder; OPC 34712; Schizophrenia

Indexed keywords

BREXPIPRAZOLE; CYTOCHROME P450 1A2 INHIBITOR; CYTOCHROME P450 INDUCER; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

AKATHISIA; ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; WEIGHT GAIN; AGONISTS; DEPRESSIVE DISORDER, MAJOR;

DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; HUMANS; QUINOLONES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; THIOPHENES;

EID: 84938677047     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.7.2358605     Document Type: Article

References (26)

1. Leucht, S., Cipriani, A., Spineli, L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896): 951-62.
2. Volavka, J., Citrome, L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert opin pharmacother 2009, 10(12): 1917-28.
3. Citrome, L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. postgrad Med 2010, 122(4): 39-48.
4. Maeda, K., Sugino, H., Akazawa, H. et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J pharmacol Exp Ther 2014, 350(3): 589-604.
5. Citrome, L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013, 27(11): 879-911.
6. Yoshimi, N., Futamura, T., Hashimoto, K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur neuropsychopharmacol 2015, 25(3): 356-64.
7. Yoshimi, N., Fujita, Y., Ohgi, Y., Futamura, T., Kikuchi, T., Hashimoto, K. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav 2014, 124: 245-9.
8. Oosterhof, C.A., El Mansari, M., Blier, P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther 2014, 351(3): 585-95.
9. Maeda, K., Lerdrup, L., Sugino, H. et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014, 350(3): 605-14.
10. Ishima, T., Futamura, T., Ohgi, Y., Yoshimi, N., Kikuchi, T., Hashimoto, K. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur neuropsychopharmacol 2015, 25(4): 505-11.
11. Kane, J.M., Skuban, A., Ouyang, J. et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015, 164(1-3): 127-35.
12. Correll, C.U., Skuban, A., Ouyang, J. et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015, 2(6): appiajp201514101275.
13. th Annu Meet Soc Biol Psychiatry (SoBp) (May 14-16, Toronto) 2015] 2015, 77(9, Suppl. 1): abst 560.
14. th Int Congr Schizophr res (March 28-april 1, Colorado Springs) 2015] 2015, 41(Suppl. 1): abst 95.
15. th annu Meet Soc Biol Psychiatry (SOBP) (May 14-16, Toronto) 2015] 2015, 77(9, Suppl. 1): abst 177.
16. th Int Congr Schizophr Res (March 28-April 1, Colorado Springs) 2015] 2015, 41(Suppl. 1): Abst 94.
17. th Annu Meet Soc Biol Psychiatry (SOBP) (May 14-16, Toronto) 2015] 2015, 77(9, Suppl.): Abst 173.
18. th Annu Meet Soc Biol Psychiatry (SOBP) (May 14-16, Toronto) 2015] 2015, 77(9, Suppl.): Abst 174.
19. th Int Congr Schizophr res (March 28-april 1, Colorado Springs) 2015] 2015, 41(Suppl. 1): abst 93.
20. rd Annu Meet Am Coll Neuropsychopharmacol (ACNP) (December 7-11, Phoenix) 2014] 2014, 39(Suppl. 1): Abst T100.
21. FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia [news release]. Lundbeck, July 11, 2015. Accessed July 13, 2015.
22. Zink, M., Englisch, S., Schmitt, A. Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Arch Psychiatry Clin Neurosci 2014, 264 (Suppl 1):S67-82.
23. Otsuka Pharmaceutical Co., Ltd. REXULTI (brexpiprazole) tablets for oral use. Prescribing information, July 2015. http://www.otsuka-us.com/products/documents/rexulti.pi.pdf. Accessed July 10, 2015.
24. US FDA accepts Otsuka and Lundbeck's filing for review of brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression [news release]. Lundbeck, September 24, 2014. Accessed June 7, 2015.
25. McQuade, R., Hobart, M., Forbes, R.A., et al. A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). 2011 US Psych Cong (November 7-10, Las Vegas) 2011, Poster 140.
26. th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst NR04-65.